| Article ID | Journal | Published Year | Pages | File Type | 
|---|---|---|---|---|
| 9161736 | Chest | 2005 | 9 Pages | 
Abstract
												IRM from NBSAP is high, and standard therapies evaluated at the time of this study resulted in poor clinical outcomes. Delayed therapy was not found to be a predictor of adverse outcomes; however, this lack of ability to detect a difference may be a product of small sample size. These findings suggest that newer agents with enhanced clinical activity in NBSAP are needed and that these should be evaluated in a real-world setting, where outcomes of the most ill patients can be assessed.
											Keywords
												Staphylococcal pneumoniaAPACHEMSSAIRMCARTVAPmethicillin-sensitive Staphylococcus aureusMRSAmethicillin-resistant Staphylococcus aureusBacteremiaICUClassification and regression tree analysisInfectionCross-infectionStaphylococcal infectionsAcute Physiology and Chronic Health EvaluationCritical careHospital mortalityClinical outcomesVentilator-associated pneumonia
												Related Topics
												
													Health Sciences
													Medicine and Dentistry
													Cardiology and Cardiovascular Medicine
												
											Authors
												DeRyke PharmD, Lodise PharmD, Rybak PharmD, MS, McKinnon PharmD, 
											